**Question:** CML treatment

**Core Concept:** Chronic myeloid leukemia (CML) is a type of cancer affecting the myeloid lineage of hematopoietic stem cells, characterized by the presence of the Philadelphia chromosome (Ph+) and the BCR-ABL1 fusion gene. Treatment options aim to target and suppress the BCR-ABL1 protein, which drives the disease progression.

**Why the Correct Answer is Right:**
The correct answer is **D.** Imatinib (Gleevec) is a tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL1 protein, blocking its function and reducing the uncontrolled proliferation of myeloid cells. Imatinib was the first-line treatment for CML and remains effective, although its efficacy may decrease over time due to resistance mechanisms.

**Why Each Wrong Option is Incorrect:**
A. **Option A (Hydroxyurea):** Hydroxyurea is a nucleoside analogue primarily used for myeloproliferative disorders like polycythemia vera and essential thrombocythemia. It does not target the BCR-ABL1 protein, making it an incorrect choice for CML treatment.

B. **Option B (Anthracyclines):** Anthracyclines are chemotherapy drugs commonly used in various cancers, including acute myeloid leukemia. They target DNA topoisomerase II, not specifically targeting BCR-ABL1. Therefore, they are not an appropriate choice for CML treatment.

C. **Option C (Cytosine arabinoside):** Cytosine arabinoside (ara-C) is an antineoplastic agent that inhibits DNA synthesis and is used in acute leukemia treatments. It does not target the BCR-ABL1 protein and is thus an incorrect choice for CML treatment.

**Clinical Pearl:** In recent years, the treatment landscape for chronic myeloid leukemia has evolved with the advent of newer TKIs like nilotinib, dasatinib, bosutinib, and ponatinib. These drugs are more effective against BCR-ABL1 and have a higher success rate in treating CML compared to hydroxyurea, anthracyclines, and cytosine arabinoside.

**Correct Answer Explanation:**
D. **Option D (Imatinib):** Imatinib is a tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL1 protein. It was the first-generation TKI approved for CML treatment, revolutionizing the field of CML management. Imatinib is effective in achieving cytogenetic and molecular remission in the majority of CML patients, making it a suitable treatment option for chronic myeloid leukemia.